<DOC>
	<DOCNO>NCT02594566</DOCNO>
	<brief_summary>If participant decides take part study , participant need follow : Visit study clinic 10 time available reasonable amount follow phone call see participant . The participant receive three dos vaccine inject muscle upper arm . After injection participant ask remain study site least 30 minute participant receives study vaccine . The result participant blood test , like laboratory test result , provide Investigators , Sponsor , vaccine developer . Positive HIV viral hepatitis test result reportable local health authority accord local law . The participant ask refrain excessive physical activity alcohol consumption within 2 day clinic visit avoid possible confusing effect laboratory test .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Cytomegalovirus DNA Vaccine</brief_title>
	<detailed_description>Up 10 normal healthy adult female subject 18 35 year age enrol trial . A total 3 injection vaccine give Days 0 , 28 ( +4 day ) , 56 ( +4 day ) . There follow-up visit 7 day vaccination , one follow-up visit 28 day 3rd ( last ) vaccination , final visit 3 month later . Blood urine sample collect vaccination follow-up visit . The participant ask complete telephone call follow-up 1 year receiving last vaccination . Participants require complete subject diary card throughout study telephone call follow-up approximately Day 420 ( i.e. , 12 month follow 3rd final dose schedule Day 56 ) . Diary card review study staff visit Day 420 telephone call .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female adult , 18 35 year age Able willing follow approximately 15 month Lack serum antibody specific CMV Able provide inform consent History receive previous CMV vaccine Pregnant , try become pregnant , breastfeed Receipt donation blood , blood product , plasma within 30 day initial injection Clinically significant finding clinical evaluation laboratory test , evidence medical disease ( ) medical/psychiatric condition ( ) , unable participate due occupation social reason Use immunomodulatory therapy ( drug suppress immune system ) within past 6 month medication nutritional supplement determine study investigator may interfere vaccine response , increase safety risk participant , take within 30 day prior initial injection Day 0 Antinuclear antibody ( ANA ) titer &gt; 1:80 Body mass index ( BMI ) &gt; 30 Less 18 year age old 35 year age No access telephone</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Congenital Infection</keyword>
</DOC>